Clinical trials: Tumor, Colorectal
Non-Small Cell Lung Cancer, Melanoma
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in participants with NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, Melanoma, Mismatch Repair-Proficient Colorectal Cancer
- Trial name
- NCT02437136
- Testing
- entinostat, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 191 people
- Sponsor
- Syndax Pharmaceuticals
Colorectal Cancer
A Phase 1/2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj.
The purpose of this open-label, dose-escalation phase I trial is to evaluate the safety, tolerability and pharmacokinetic profiles and to assess the efficacy of CKD-516 Tablet in Combination with Irinotecan inj.
- Trial name
- NCT03076957
- Testing
- CKD-516 Tablet
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC
Colon Cancer, Rectal Cancer
Clinical Study-evaluate Performance&Safety "Aer-O-Scope" in Colon of Low Risk Patients
A double center study to evaluate the safety and efficacy of the Aer-O-Scope in traveling through the colon in low risk subjects.
- Trial name
- NCT00867724
- Testing
- Aer-O-Scope Colonoscopy
- Where
- Israel
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GI View Ltd.
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Metastatic Colorectal Cancer
Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC
Trial design: Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with "Hyaluronic acid-Irinotecan" or "HA-Irinotecan") regimen. Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve.
- Trial name
- FOLF(HA)iri (NCT01290783)
- Testing
- Irintoecan, HA-Irinotecan solution for Infusion
- Where
- 5 sites in Australia
- Volunteers
- 390 people
- Sponsor
- Alchemia Oncology
Breast Cancer, Prostate Cancer
A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors
This is a Phase 1-1b multicenter clinical study to evaluate the safety, efficacy, and dosimetry of [177Lu]Lu-A9-0631 and [225Ac]Ac-0642 in participants with Gastrin-Releasing Peptide Receptor (GRPR) expressing locally advanced…
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer, GRPR-positive Solid Tumors
- Trial name
- NCT07661641
- Testing
- [68Ga]Ga-A9-6217, Low dose [177Lu]Lu-A9-0631, [177Lu]Lu-A9-0631
- Where
- 2 sites in Australia
- Volunteers
- 115 people
- Sponsor
- Alpha-9 Oncology USA Inc.
Non-small Cell Lung Cancer, Metastatic Colorectal Cancer
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
This is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab biosimilar) in domestic patients with non-small cell lung…
- Conditions
- Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Kidney Cancer
- Trial name
- NCT04889495
- Testing
- Zirabev
- Sponsor
- Pfizer
Neoplasm Metastasis
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
- Trial name
- NCT04458259
- Testing
- PF-07265807, Sasanlimab, Axitinib
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 88 people
- Sponsor
- Pfizer
Colon Neoplasms
AI-Assisted Microbiome Analysis for Evaluating the Efficacy of MPRO3 and Gut Environmental Changes in Colon Cancer Surgery Patients
The goal of this clinical trial is to evaluate the effects of MPRO3(probiotics mixture) supplementation on surgical outcomes and gut health in patients undergoing surgery for colon cancer.The main question is whether MPRO3…
- Trial name
- AI-MPRO3 (NCT07792980)
- Testing
- MPRO3
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- hy Co., LTD.
Colorectal Cancer Screening
Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection
The PROCEED-CRC study will prospectively collect blood samples from participants who are at average risk of colorectal cancer (CRC). Samples will be used for research use and the development of a blood-based CRC screening test.
- Trial name
- PROCEED-CRC (NCT06620627)
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Natera, Inc.
Advanced Solid Tumor, Metastatic Cancer
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the…
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT04464967
- Testing
- SNK01, Trastuzumab, Cetuximab
- Sponsor
- NKGen Biotech, Inc.
Metastatic Gastric Cancer, Metastatic Breast Cancer
Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
The purpose of this clinical study is to assess the safety and tolerability and efficacy of active immunotherapy with dose escalation and cohort expansion of OBI-833 in advanced/metastatic gastric, lung, colorectal, or breast…
- Conditions
- Metastatic Gastric Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Lung Cancer
- Trial name
- NCT02310464
- Testing
- OBI-833/OBI-821
- Where
- 4 sites in Taiwan
- Volunteers
- 25 people
- Sponsor
- OBI Pharma, Inc
Colorectal Cancer, Metastatic Colorectal Cancer
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil [5-FU], and leucovorin (FOLFIRI) and bevacizumab for…
- Trial name
- NCT05593328
- Testing
- Onvansertib, FOLFIRI, Bevacizumab
- Where
- 27 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cardiff Oncology
Solid Tumor, Adult, Triple Negative Breast Cancer
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced…
- Conditions
- Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT04282044
- Testing
- CRX100 suspension for infusion, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioEclipse Therapeutics
Head and Neck Cancer, Lung Cancer
Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors
This pilot phase II study is designed as a test and retest study to investigate [F 18]HX4 as a reliable non-invasive PET imaging marker for detection of tumor hypoxia regions and to establish a threshold for [F 18]HX4 uptake in…
- Conditions
- Head and Neck Cancer, Lung Cancer, Liver Cancer, Rectal Cancer
- Trial name
- HX4-200 (NCT01075399)
- Testing
- [F 18]HX4
- Volunteers
- 50 people
- Sponsor
- Siemens Molecular Imaging
Colorectal Cancer (Diagnosis)
Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study
The primary objective of this study is to evaluate a blood-based screening test for Colorectal Cancer (CRC).
- Trial name
- CLEAR (NCT07479381)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Harbinger Health
Advanced/Metastatic Solid Tumor
KZR-261 in Subjects With Advanced Solid Malignancies
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase…
- Trial name
- NCT05047536
- Testing
- KZR-261
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Kezar Life Sciences, Inc.
Familial Adenomatous Polyposis
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
The purpose of this randomized, double-blind, Phase III trial is to determine if the combination of eflornithine plus sulindac is superior to sulindac or eflornithine as single agents in delaying time to the first occurrence of…
- Trial name
- NCT01483144
- Testing
- Eflornithine, Sulindac 150 MG
- Where
- 17 sites in United States, Belgium and 5 more
- Volunteers
- 171 people
- Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
KRAS Mutant Metastatic Colorectal Cancer
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
This is a Phase 1 dose-escalation study with three dose levels to determine the maximum tolerated dose of REOLYSIN® combined with FOLFIRI and bevacizumab.
- Trial name
- NCT01274624
- Testing
- REOLYSIN®, Irinotecan, Leucovorin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Oncolytics Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.